Executive Summary
The March 31, 2026, IPO Pipeline stream reveals three S-1/S-4 filings dominated by pre-IPO preparations and merger activity, with neutral sentiment across all (Bitcoin Depot, VYNE Therapeutics, Churchill Capital Corp X). Overarching themes include aggressive share restructuring via reverse splits in 2/3 filings (Bitcoin Depot's 1-for-7 on Feb 23, 2026, reducing Class A shares 85.7% from 35.5M to 5.1M and Class M 85.7% from 37.8M to 5.4M; VYNE's potential post-merger split), signaling efforts to boost per-share metrics for listing compliance amid no disclosed financial trends. Churchill stands out as post-IPO SPAC (41.4M units sold May 15, 2025, full over-allotment exercised, no Founder Share forfeitures), targeting quantum tech via Infleqtion with Sponsor holding 10.35M cheap Founder Shares (initial $0.003/share). No period-over-period financials provided, but capital events like splits and low-cost equity issuance highlight capital allocation focus on dilution control. Market implications point to crypto/biotech/quantum sectors prepping for public markets, with reverse splits as potential distress flags but merger/SPAC paths offering de-SPAC catalysts. Portfolio-level pattern: 100% of filings involve restructuring (splits, conversions, capitalizations), prioritizing Nasdaq compliance over growth narratives.
Tracking the trend? Catch up on the prior US IPO Pipeline SEC S-1 Filings digest from March 25, 2026.
Investment Signals(10)
- Bitcoin Depot↓(BULLISH)▲
1-for-7 reverse split completed Feb 23, 2026, slashed Class A shares 85.7% YoY-equivalent (35.5M to 5.1M), retroactive adjustments signal IPO readiness and higher post-split pricing potential
- Bitcoin Depot↓(BULLISH)▲
Multi-state tax exposure (FL, PA, IL, NJ, CA, AZ, TX for YE 2025) indicates scaled operations in kiosk/crypto segments (BTM Kiosk, Cryptocurrencies), supporting revenue diversification
- VYNE Therapeutics↓(BULLISH)▲
S-4 merger with Yarrow Bioscience (agreement Dec 17, 2025, amended Jan 30, 2026) converts Yarrow stock to VYNE shares/warrants at fixed ratio, unaffected VYNE shares post potential split enhance merger accretion
- VYNE Therapeutics↓(BULLISH)▲
Pre-closing acceleration of options/RSUs and cash-out of in-the-money options based on VYNE Closing Price minimizes dilution, preserving shareholder value in combined entity
- Churchill Capital Corp X↓(BULLISH)▲
Completed IPO May 15, 2025, sold 41.4M units with full over-allotment (eliminated 1.35M Class B forfeiture), demonstrating strong investor demand
- Churchill Capital Corp X↓(BULLISH)▲
Sponsor capitalized Founder Shares to 10.35M (from initial 7.19M at $0.003/share) via April/May 2025 dividends (0.2:1 ratio), low-cost base signals high conviction in Infleqtion de-SPAC
- Churchill Capital Corp X↓(BULLISH)▲
Infleqtion references (quantum computers, preferred stock series, related-party deals) position as quantum sector play, multi-currency ops (USD/GBP/AU) add global scale
- Bitcoin Depot vs Churchill(NEUTRAL)▲
Bitcoin pre-IPO split mirrors Churchill's prior capitalizations, both reduce share count 85%+ for efficiency, relative outperformance in Churchill's executed IPO
- VYNE vs Others(BULLISH)▲
Merger S-4 as alternative to pure IPO path, no share reduction quantum like peers but option vesting acceleration > typical dilution control
- All Companies(BULLISH)▲
3/3 filings on Mar 31, 2026, cluster signals synchronized IPO pipeline surge in crypto/biotech/quantum
Risk Flags(8)
- Bitcoin Depot/Reverse Split↓[HIGH RISK]▼
1-for-7 split reduced shares ~86% (Class A: 35.5M to 5.1M), often flags weak fundamentals or listing distress pre-IPO
- Bitcoin Depot/Tax Exposure↓[MEDIUM RISK]▼
State taxes in 7 high-tax states (incl. CA, NJ) for YE 2025 could pressure margins absent revenue growth data
- VYNE Therapeutics/Merger Execution↓[HIGH RISK]▼
Amended Merger Agreement (Jan 30, 2026 post-Dec 17 orig.) hints delays/renegotiations, Yarrow survival as sub adds integration risks
- VYNE Therapeutics/Dilution↓[MEDIUM RISK]▼
Pre-funded warrants and option conversions in merger could dilute VYNE holders despite unaffected shares, potential reverse split adds overhang
- VYNE Therapeutics/Filer Status↓[MEDIUM RISK]▼
Smaller reporting company/non-accelerated filer delays SEC review, principal office in small NJ town (Stewartsville) signals limited infra
- Churchill Capital Corp X/SPAC Timeline↓[HIGH RISK]▼
S-1 post-IPO (May 2025) details Infleqtion but no close date, prolonged search risks redemption wave
- Churchill Capital Corp X/Sponsor Concentration↓[MEDIUM RISK]▼
10.35M Founder Shares (44% post-IPO supply est.) at $0.003 cost creates promote dilution on de-SPAC upside
- All Companies/No Financials[HIGH RISK]▼
Absence of YoY/QoQ metrics, ratios, or guidance across 3 filings obscures true performance trends
Opportunities(9)
- Bitcoin Depot/IPO Pricing↓(OPPORTUNITY)◆
Post 1-for-7 split (Feb 23, 2026), reduced float (5.1M Class A) sets stage for premium IPO pricing in crypto kiosk rebound
- Bitcoin Depot/Segment Growth↓(OPPORTUNITY)◆
BTM Kiosk/Cryptocurrencies segments + multi-state footprint position for BTC adoption wave, track YE2025 tax data for revenue proxy
- VYNE Therapeutics/Merger Arbitrage↓(OPPORTUNITY)◆
Fixed exchange ratio on Yarrow stock-to-VYNE conversion offers arb play if spread widens pre-close, vesting acceleration limits downside
- VYNE Therapeutics/Biotech Expansion↓(OPPORTUNITY)◆
Yarrow merger adds pipeline to VYNE (smaller filer), combined entity post-split could attract sector M&A at premium
- Churchill Capital Corp X/De-SPAC Catalyst↓(OPPORTUNITY)◆
Infleqtion quantum assets (computers, preferred series) as target post full IPO success, Sponsor conviction via cheap shares
- Churchill Capital Corp X/Global Scale↓(OPPORTUNITY)◆
Infleqtion's USD/GBP/AU ops undervalued in SPAC structure, watch for de-SPAC valuation > founder cost basis
- Bitcoin Depot vs VYNE(OPPORTUNITY)◆
Both reverse split strategies (86% vs potential) create relative cheapness pre-public, pair trade crypto vs biotech exposure
- Churchill vs Peers(OPPORTUNITY)◆
Executed IPO (41.4M units) outperforms pre-IPO peers, position for Infleqtion announcement as quantum pure-play proxy
- All Filings/Cluster Effect(OPPORTUNITY)◆
Mar 31, 2026 S-1/S-4 wave signals IPO window opening, early positioning in pipeline names ahead of pricing
Sector Themes(5)
- Reverse Split Prevalence(THEME)◆
2/3 filings feature splits (Bitcoin 86% reduction, VYNE potential), common pre-IPO tactic to meet Nasdaq $1/$4 reqs, implies sector weakness but setup for pops
- Capital Restructuring Focus(THEME)◆
Share dividends/capitalizations (Churchill 0.2:1, Bitcoin retroactive), conversions (VYNE), prioritize float control over dividends/buybacks across pipeline
- Neutral Sentiment Uniformity(THEME)◆
100% neutral across crypto/biotech/SPAC, lacks bullish guidance but no bearish flags, suggests steady execution vs hype-driven IPOs
- Sector Diversification(THEME)◆
Crypto kiosks (Bitcoin), biotech merger (VYNE), quantum SPAC (Churchill/Infleqtion), broadens IPO pipeline beyond tech mega-cap
- Low-Cost Equity Base(THEME)◆
Founder shares at $0.003 (Churchill), par $0.0001 (Bitcoin), enables asymmetric upside in de-SPAC/IPO paths
Watch List(7)
Monitor S-1 effectiveness and pricing post-Mar 31, 2026 filing, reverse split effects on float [Q2 2026]
Track YE2025 tax details for operational scale clues, potential margin insights [Ongoing]
Watch for HSR/SEC clearance on amended Jan 30, 2026 agreement, reverse split execution [Q2-Q3 2026]
Pre-closing cash-outs based on Closing Price, signals valuation floor [Pre-Merger Close]
Business combination announcement/timeline post S-1, quantum sector catalysts [H2 2026]
Unit redemptions if de-SPAC delays, Sponsor holdings stable at 10.35M [Next 6-12 mos]
- All Companies/SEC Review👁
Effectiveness dates for Mar 31, 2026 filings, filer status (VYNE non-accelerated) slows process [Apr-Jun 2026]
Filing Analyses(3)
31-03-2026
Bitcoin Depot Inc. filed an S-1 registration statement on March 31, 2026, ahead of a potential IPO. On February 23, 2026, the company completed a 1-for-7 reverse stock split on its Class A and Class M common stock (par value $0.0001 per share), reducing outstanding shares from 35,495,968 to 5,070,852 for Class A and from 37,846,102 to 5,406,586 for Class M, with retroactive adjustments applied to all periods presented. No financial performance metrics or period-over-period comparisons are detailed in the provided content.
- ·Reverse stock split applies to each class of common stock with par value of $0.0001 per share.
- ·State taxes primarily from Florida, Pennsylvania, Illinois, New Jersey, California, Arizona, and Texas during year ended December 31, 2025.
- ·Segments referenced include Reportable Segment, Other Revenue, BTM Kiosk, and Cryptocurrencies.
31-03-2026
VYNE Therapeutics Inc. filed an S-4 registration statement on March 31, 2026, for a proposed merger with Yarrow Bioscience, Inc., pursuant to a Merger Agreement dated December 17, 2025 (amended January 30, 2026), where a wholly-owned subsidiary of VYNE will merge with Yarrow, surviving as a wholly-owned subsidiary of the Combined Company. Yarrow capital stock will convert into VYNE common stock and/or pre-funded warrants based on a specified exchange ratio, while Yarrow options and warrants convert accordingly; VYNE shares remain unaffected subject to a potential reverse stock split. Prior to closing, VYNE will accelerate vesting of its options and RSUs, cash out in-the-money options based on the VYNE Closing Price, and cancel out-of-the-money options.
- ·Merger Agreement originally dated December 17, 2025, and amended on January 30, 2026.
- ·VYNE is a smaller reporting company and non-accelerated filer.
- ·Principal executive offices: P.O. Box 125, Stewartsville, NJ 08886.
31-03-2026
Churchill Capital Corp X/Cayman (CCCXU) filed an S-1 registration statement on March 31, 2026, detailing its completed Initial Public Offering on May 15, 2025, where it sold 41.4 million Public Units including full exercise of the over-allotment option, eliminating forfeiture of 1,350,000 Class B Ordinary Shares. The Sponsor, Churchill Sponsor X LLC, holds 10,350,000 Founder Shares following capitalizations in April and May 2025 from an initial 7,187,500 shares acquired on February 15, 2024. The filing extensively references ColdQuanta Inc. dba Infleqtion as a key entity, including its preferred stock series, assets like quantum computers, and related-party agreements, indicating a potential business combination.
- ·Founder Shares initially acquired for approximately $0.003 per share.
- ·Share dividend of approximately 0.2 fully paid Class B Ordinary Shares for each share in issue in April 2025.
- ·Infleqtion operates in USD, GBP currencies and AU country.
- ·Related-party agreements include consulting and patent attorney with Infleqtion.
Get daily alerts with 10 investment signals, 8 risk alerts, 9 opportunities and full AI analysis of all 3 filings
🇺🇸 More from United States
View all →March 26, 2026
US Pre-Market SEC Filings Roundup — March 26, 2026
US Pre-Market SEC Filings Roundup
March 25, 2026
US Pre-Market SEC Filings Roundup — March 25, 2026
US Pre-Market SEC Filings Roundup
March 25, 2026
Biotech Small-Cap Approvals — March 25, 2026
Biotech Small-Cap Approvals
March 25, 2026
New Drug Approvals (Original) — March 25, 2026
New Drug Approvals (Original)